Fenoterol, ipratropium (Duovent Hfa, Atrovent Beta U.D.V.)
Fenoterol, ipratropium
Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale
Every registration of this product has been cancelled.
Registration
- Applicant
- Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Duovent hfa EACH METERED DOSE CONTAINS: FENOTEROL HYDROBROMIDE 50,0 ug, IPRATROPIUM BROMIDE 20,0 ug | Not listed | 35030235/10.2.1/0302 | Cancelled | Not determined | None |
| Atrovent beta U.D.V. EACH VIAL CONTAINS FENOTEROL HYDROBROMIDE 1,25 mg IPRATROPIUM BROMIDE 0,5 mg | Not listed | Z0078Z/10.2.1/78 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Fenoterol
- when intended for the prevention or delay of labour, and preparations thereof for injection.
Consolidated Schedules 06 July 2026, line 6324
S3: Fenoterol
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 3576
S3: Ipratropium
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 3804
S2: Fenoterol
- when contained in respirator solutions; (S3) and
- when intended for injection or for the prevention or delay of labour. (S4)
Consolidated Schedules 06 July 2026, lines 1984 to 1988
S2: Ipratropium
- except when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 2177
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.